– Collaboration and communication with non-EU regulatory authorities, in particular by providing support to the ICH initiative and to the PERF initiative, and by strengthening communication with the US Food and Drug Administration by means of regular videoconferences and mechanisms of urgent information exchange • Safety Working Party – Revision and development of draft ICH safety-related guidelines on behalf of CPMP.